| Disease | IN A DOUBLE-BLIND, VEHICLE-CONTROLLED, MULTICENTER STUDY [OLSEN ET AL.1991], 176 PATIENTS WERE ENROLLED, WITH MASOPROCOL OR VEHICLE IN A 3:1 RATIO, 131 IN MASOPROCOL GROUP (M) AND 45 IN VEHICLE GROUP (V). PATIENTS HAD A MIMIMUM OF 5 LESIONS ON THE
FACE AND/OR NECK, EACH AT LEAST 5 MM IN DIAMETER. THEY APPLIED THE MEDICATION TWICE DAILY. THERE WAS A MEAN DECREASE IN ABSOLUTE LESION COUNTS OF 9.6 IN MASOPROCOL GROUP VERSUS 2.3 IN VECHICLE GROUP(P<0.0001). THE MEDIAN PERCENT REDUCTION IN
LESIONS WAS 71.4% FOR MASOPROCOL GROUP VERSUS 4.3% FOR THE VEHICLE GROUP (P<0.0003). IN THE MASOPROCOL GROUP, 11% OF PATIENTS WERE CURED, 50% WITH MARKED IMPROVEMENT, 21% WITH MODERATE IMPROVEMENT, 14% WITH SLIGHT IMPROVEMENT AND 4% WITH NO CHANGE.
A COMMERCIAL PRODUCT, ACTINEX, WAS USED. |